-
1
-
-
84862651150
-
Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis
-
L ovell RM, Ford AC . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.
-
(2012)
Clin Gastroenterol Hepatol
, vol.10
, pp. 712-721
-
-
Ovell, R.M.L.1
Ford, A.C.2
-
3
-
-
60449087280
-
Burden of digestive diseases in the United States part II: Lower gastrointestinal diseases
-
E verhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009;136:741-54.
-
(2009)
Gastroenterology
, vol.136
, pp. 741-754
-
-
Verhart, J.E.E.1
Ruhl, C.E.2
-
4
-
-
0033866061
-
The impact of irritable bowel syndrome on health-related quality of life
-
G ralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60.
-
(2000)
Gastroenterology
, vol.119
, pp. 654-660
-
-
Ralnek, I.M.G.1
Hays, R.D.2
Kilbourne, A.3
-
5
-
-
84937013009
-
Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation
-
Singh P, Staller K, Barshop K, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol 2015;21:8103-9.
-
(2015)
World J Gastroenterol
, vol.21
, pp. 8103-8109
-
-
Singh, P.1
Staller, K.2
Barshop, K.3
-
6
-
-
84926421572
-
Faecal incontinence\-The hidden scourge of irritable bowel syndrome: A cross-sectional study
-
A tarodi S, Rafieian S, Whorwell PJ. Faecal incontinence\-The hidden scourge of irritable bowel syndrome: a cross-sectional study. BMJ Open Gastroenterol 2014;1:e000002.
-
(2014)
BMJ Open Gastroenterol
, vol.1
, pp. e000002
-
-
Tarodi, S.A.1
Rafieian, S.2
Whorwell, P.J.3
-
7
-
-
85012930438
-
Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea
-
Buono JL, Carson RT , Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes 2017;15:35.
-
(2017)
Health Qual Life Outcomes
, vol.15
, pp. 35
-
-
Buono, J.L.1
Carson, R.T.2
Flores, N.M.3
-
8
-
-
85017653669
-
Eluxadoline efficacy in ibs-d patients who report prior loperamide use
-
L acy BE, Chey WD, Cash BD, et al. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol 2017;112:924-32.
-
(2017)
Am J Gastroenterol
, vol.112
, pp. 924-932
-
-
Acy, B.E.L.1
Chey, W.D.2
Cash, B.D.3
-
9
-
-
85049076072
-
Acg task force on management of irritable bowel syndrome
-
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
-
Ford AC , Moayyedi P, Chey WD, et al. ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol 2018;113(Suppl 2):1-18.
-
(2018)
Am J Gastroenterol
, vol.113
, pp. 1-18
-
-
Ford, A.C.1
Moayyedi, P.2
Chey, W.D.3
-
10
-
-
85053356383
-
Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis
-
Ford AC , Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019;114:21-39.
-
(2019)
Am J Gastroenterol
, vol.114
, pp. 21-39
-
-
Ford, A.C.1
Lacy, B.E.2
Harris, L.A.3
-
11
-
-
57749192461
-
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis
-
Ford AC , Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313-92.
-
(2008)
BMJ
, vol.337
, pp. a2313-a2392
-
-
Ford, A.C.1
Talley, N.J.2
Spiegel, B.M.3
-
12
-
-
0033625752
-
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
-
Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-82.
-
(2000)
Aliment Pharmacol Ther
, vol.14
, pp. 775-782
-
-
Houghton, L.A.1
Foster, J.M.2
Whorwell, P.J.3
-
13
-
-
84927797008
-
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
-
Min YW, Rhee PL. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol 2015;8:136-42.
-
(2015)
Therap Adv Gastroenterol
, vol.8
, pp. 136-142
-
-
Min, Y.W.1
Rhee, P.L.2
-
14
-
-
0031658491
-
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
-
Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55.
-
(1998)
Aliment Pharmacol Ther
, vol.12
, pp. 849-855
-
-
Delvaux, M.1
Louvel, D.2
Mamet, J.P.3
-
15
-
-
84961197854
-
Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
-
Kane JS, Ford AC . Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2016;10:431-42.
-
(2016)
Expert Rev Gastroenterol Hepatol
, vol.10
, pp. 431-442
-
-
Kane, J.S.1
Ford, A.C.2
-
16
-
-
85030873237
-
Eluxadoline in irritable bowel syndrome with diarrhea: Rationale, evidence and place in therapy
-
Barshop K, Staller K. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Ther Adv Chronic Dis 2017;8:153-60.
-
(2017)
Ther Adv Chronic Dis
, vol.8
, pp. 153-160
-
-
Barshop, K.1
Staller, K.2
-
17
-
-
78650864077
-
Rifaximin therapy for patients with irritable bowel syndrome without constipation
-
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
-
(2011)
N Engl J Med
, vol.364
, pp. 22-32
-
-
Pimentel, M.1
Lembo, A.2
Chey, W.D.3
-
18
-
-
0034712539
-
Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
-
C amilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
-
(2000)
Lancet
, vol.355
, pp. 1035-1040
-
-
Amilleri, M.C.1
Northcutt, A.R.2
Kong, S.3
-
19
-
-
84975861217
-
Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women
-
Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology 2016;150:358-66.
-
(2016)
Gastroenterology
, vol.150
, pp. 358-366
-
-
Fukudo, S.1
Kinoshita, Y.2
Okumura, T.3
-
20
-
-
84957818149
-
Eluxadoline for irritable bowel syndrome with diarrhea
-
L embo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med 2016;374:242-53.
-
(2016)
N Engl J Med
, vol.374
, pp. 242-253
-
-
Embo, A.J.L.1
Lacy, B.E.2
Zuckerman, M.J.3
-
21
-
-
67650455908
-
Efficacy of 5-ht3 antagonists and 5-ht4 agonists in irritable bowel syndrome: Systematic review and meta-analysis
-
Ford AC , Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1831-1843
-
-
Ford, A.C.1
Brandt, L.J.2
Young, C.3
-
22
-
-
85053338498
-
Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: Systematic review and network meta-analysis
-
Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology 2018;155:1753-63.
-
(2018)
Gastroenterology
, vol.155
, pp. 1753-1763
-
-
Black, C.J.1
Burr, N.E.2
Quigley, E.M.M.3
-
23
-
-
77953773581
-
Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome
-
Ford AC , Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58.
-
(2010)
Aliment Pharmacol Ther
, vol.32
, pp. 144-158
-
-
Ford, A.C.1
Moayyedi, P.2
-
25
-
-
84932084410
-
The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations
-
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
-
(2015)
Ann Intern Med
, vol.162
, pp. 777-784
-
-
Hutton, B.1
Salanti, G.2
Caldwell, D.M.3
-
27
-
-
85164560670
-
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool
-
Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97.
-
(2012)
Res Synth Methods
, vol.3
, pp. 80-97
-
-
Salanti, G.1
-
28
-
-
78650509651
-
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial
-
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
-
(2011)
J Clin Epidemiol
, vol.64
, pp. 163-171
-
-
Salanti, G.1
Ades, A.E.2
Ioannidis, J.P.3
-
29
-
-
84884879422
-
Graphical tools for network meta-analysis in STATA
-
C haimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654.
-
(2013)
PLoS One
, vol.8
, pp. e76654
-
-
Haimani, A.C.1
Higgins, J.P.2
Mavridis, D.3
-
30
-
-
84875625927
-
Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies
-
Higgins JP, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.
-
(2012)
Res Synth Methods
, vol.3
, pp. 98-110
-
-
Higgins, J.P.1
Jackson, D.2
Barrett, J.K.3
-
31
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
-
(2003)
BMJ
, vol.327
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
-
32
-
-
84938378742
-
Ranking treatments in frequentist network meta-analysis works without resampling methods
-
R ücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 2015;15:58.
-
(2015)
BMC Med Res Methodol
, vol.15
, pp. 58
-
-
Ücker, G.R.1
Schwarzer, G.2
-
33
-
-
85060660745
-
-
Quantitative synthesis-an update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD: Agency for Healthcare Research and Quality (US)
-
Morton SC, Murad MH, O'Connor E, et al. AHRQ methods for effective health care. Quantitative synthesis-an update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD: Agency for Healthcare Research and Quality (US), 2018.
-
(2018)
AHRQ Methods for Effective Health Care
-
-
Morton, S.C.1
Murad, M.H.2
O'Connor, E.3
-
34
-
-
0034917335
-
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
-
C amilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
-
(2001)
Arch Intern Med
, vol.161
, pp. 1733-1740
-
-
Amilleri, M.C.1
Chey, W.Y.2
Mayer, E.A.3
-
35
-
-
0032848856
-
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist
-
C amilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 1149-1159
-
-
Amilleri, M.C.1
Mayer, E.A.2
Drossman, D.A.3
-
36
-
-
8744229903
-
Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome
-
C hey WD, Chey WY, Heath AT , et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-203.
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 2195-2203
-
-
Hey, W.D.C.1
Chey, W.Y.2
Heath, A.T.3
-
37
-
-
13744263696
-
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS
-
C hang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-23.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 115-123
-
-
Hang, L.C.1
Ameen, V.Z.2
Dukes, G.E.3
-
38
-
-
0034827794
-
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome
-
Lotronex Investigator Team
-
L embo T, Wright RA, Bagby B, et al. Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
-
(2001)
Am J Gastroenterol
, vol.96
, pp. 2662-2670
-
-
Embo, T.L.1
Wright, R.A.2
Bagby, B.3
-
39
-
-
34547626592
-
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant ibs
-
Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19.
-
(2007)
Am J Gastroenterol
, vol.102
, pp. 1709-1719
-
-
Krause, R.1
Ameen, V.2
Gordon, S.H.3
-
40
-
-
52149088774
-
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both Male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
-
Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both Male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-11.
-
(2008)
Scand J Gastroenterol
, vol.43
, pp. 1202-1211
-
-
Matsueda, K.1
Harasawa, S.2
Hongo, M.3
-
41
-
-
48049093262
-
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese Male and female patients with diarrhea-predominant irritable bowel syndrome
-
Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese Male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35.
-
(2008)
Digestion
, vol.77
, pp. 225-235
-
-
Matsueda, K.1
Harasawa, S.2
Hongo, M.3
-
42
-
-
84901199541
-
Effect of ramosetron on stool consistency in Male patients with irritable bowel syndrome with diarrhea
-
Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in Male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014;12:953-9.
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, pp. 953-959
-
-
Fukudo, S.1
Ida, M.2
Akiho, H.3
-
43
-
-
85013339837
-
Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study
-
Fukudo S, Matsueda K, Haruma K, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study. Neurogastroenterol Motil 2017;29:e13023.
-
(2017)
Neurogastroenterol Motil
, vol.29
, pp. e13023
-
-
Fukudo, S.1
Matsueda, K.2
Haruma, K.3
-
44
-
-
84880633982
-
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study
-
Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013;145:329-38.
-
(2013)
Gastroenterology
, vol.145
, pp. 329-338
-
-
Dove, L.S.1
Lembo, A.2
Randall, C.W.3
-
45
-
-
84957969209
-
Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: What is their role in clinical practice alongside alosetron?
-
C ash BD, Lacy BE, Rao T, et al. Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother 2016;17:311-22.
-
(2016)
Expert Opin Pharmacother
, vol.17
, pp. 311-322
-
-
Ash, B.D.C.1
Lacy, B.E.2
Rao, T.3
-
46
-
-
84969416291
-
Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea
-
C amilleri M, Krause R, Deveze S, et al. Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea. Am J Gastroenterol 2014;109:S535.
-
(2014)
Am J Gastroenterol
, vol.109
, pp. S535
-
-
Amilleri, M.C.1
Krause, R.2
Deveze, S.3
-
47
-
-
85082729029
-
Efficacy and safety of eluxadoline in ibs-d patients who report inadequate symptom control with prior loperamide use: A phase 4, multicenter, multinational, randomized, placebo-controlled, double-blinded study (relief): Presidential poster award
-
Brenner D, Gutman C, Jo E. Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Inadequate Symptom Control With Prior Loperamide Use: A Phase 4, Multicenter, Multinational, Randomized, Placebo-controlled, Double-blinded Study (RELIEF): Presidential Poster Award. Am J Gastroenterol 2018;113(Supplement):S254-5.
-
(2018)
Am J Gastroenterol
, vol.113
, pp. S254-S255
-
-
Brenner, D.1
Gutman, C.2
Jo, E.3
-
48
-
-
85122939744
-
Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome
-
A costa A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 2016;7:e173.
-
(2016)
Clin Transl Gastroenterol
, vol.7
, pp. e173
-
-
Costa, A.A.1
Camilleri, M.2
Shin, A.3
-
49
-
-
84902269125
-
Antibiotic treatment of constipation-predominant irritable bowel syndrome
-
Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278-85.
-
(2014)
Dig Dis Sci
, vol.59
, pp. 1278-1285
-
-
Pimentel, M.1
Chang, C.2
Chua, K.S.3
-
50
-
-
84880316644
-
Conceptual and technical challenges in network meta-analysis
-
C ipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7.
-
(2013)
Ann Intern Med
, vol.159
, pp. 130-137
-
-
Ipriani, A.C.1
Higgins, J.P.2
Geddes, J.R.3
-
51
-
-
0035822324
-
Assessing the quality of controlled clinical trials
-
Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
-
(2001)
BMJ
, vol.323
, pp. 42-46
-
-
Juni, P.1
Altman, D.G.2
Egger, M.3
-
52
-
-
84883376111
-
A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program
-
T ong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013;6:344-57.
-
(2013)
Therap Adv Gastroenterol
, vol.6
, pp. 344-357
-
-
Ong, K.T.1
Nicandro, J.P.2
Shringarpure, R.3
-
53
-
-
1942440353
-
Occurrence of colon ischemia in relation to irritable bowel syndrome
-
C ole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004;99:486-91.
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 486-491
-
-
Ole, J.A.C.1
Cook, S.F.2
Sands, B.E.3
-
54
-
-
84907499626
-
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
-
G arsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014;63:1617-25.
-
(2014)
Gut
, vol.63
, pp. 1617-1625
-
-
Arsed, K.G.1
Chernova, J.2
Hastings, M.3
-
55
-
-
85076449233
-
-
R andomized, double-blind, placebo-controlled phase 2 trial of BEKINDA (ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D)
-
R andomized, double-blind, placebo-controlled phase 2 trial of BEKINDA (ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D). https://clinicaltrialsgov/ct2/show/ NCT02757105?term=ondansetron&cond=Irritable+Bowel+Syndrome&rank=2.
-
-
-
-
56
-
-
85076448873
-
-
T reatment of irritable bowel syndrome with diarrhoea using titrated ondansetron trial (TRITON)
-
T reatment of irritable bowel syndrome with diarrhoea using titrated ondansetron trial (TRITON). https://clinicaltrialsgov/ct2/show/ NCT03555188?term=ondansetron&cond=Irritable+Bowel+Syndrome&rank=1.
-
-
-
-
57
-
-
0032829725
-
Functional bowel disorders and functional abdominal pain
-
T hompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):ii43-7.
-
(1999)
Gut
, vol.45
, pp. ii43-ii47
-
-
Hompson, W.G.T.1
Longstreth, G.F.2
Drossman, D.A.3
-
59
-
-
0025601811
-
Identification of sub-groups of functional gastrointestinal disorders
-
Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterology Intl 1990;3:159-72.
-
(1990)
Gastroenterology Intl
, vol.3
, pp. 159-172
-
-
Drossman, D.A.1
Thompson, W.G.2
Talley, N.J.3
-
60
-
-
84888299584
-
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care
-
Ford AC , Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013;145:1262-70.
-
(2013)
Gastroenterology
, vol.145
, pp. 1262-1270
-
-
Ford, A.C.1
Bercik, P.2
Morgan, D.G.3
-
61
-
-
0032749795
-
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
-
Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27.
-
(1999)
Aliment Pharmacol Ther
, vol.13
, pp. 1419-1427
-
-
Jones, R.H.1
Holtmann, G.2
Rodrigo, L.3
-
62
-
-
81855185606
-
Efficacy of ramosetron in the treatment of Male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine
-
L ee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of Male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104.
-
(2011)
Neurogastroenterol Motil
, vol.23
, pp. 1098-1104
-
-
Ee, K.J.L.1
Kim, N.Y.2
Kwon, J.K.3
-
63
-
-
85057305718
-
Alosetron versus traditional pharmacotherapy in clinical practice: Effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome
-
Olden KW, Chey WD, Shringarpure R, et al. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin 2019;35:461-72.
-
(2019)
Curr Med Res Opin
, vol.35
, pp. 461-472
-
-
Olden, K.W.1
Chey, W.D.2
Shringarpure, R.3
-
64
-
-
85049731293
-
Assessing the efficacy of peripherally acting μ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: Authors reply
-
Burr NE, Ford AC . Assessing the efficacy of peripherally acting μ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. Gut 2019;68:1530-1.
-
(2019)
Gut
, vol.68
, pp. 1530-1531
-
-
Burr, N.E.1
Ford, A.C.2
|